Association of Combined Anti‐Ro52 / TRIM21 and Anti‐Ro60 / SSA Antibodies With Increased Sjögren Disease Severity Through Interferon Pathway Activation
Arthritis & Rheumatology · 2024-05 · 76 (5) · 751-762
DOI: 10.1002/art.42789 ↗Kurz gefasst
Fachartikel in der Zeitschrift Arthritis & Rheumatology, online erschienen am 14.02.2024. Verfasst von Eléonore Bettacchioli und 12 weiteren Autor:innen. Beteiligte Einrichtung: LBAI, UMR1227, INSERM, University of Western Brittany, Brest, France, and Centre Hospitalier Universitaire de Brest, Brest, France. Hauptthemen laut MEDLINE: Sjogren's Syndrome, Ribonucleoproteins, Severity of Illness Index, Interferons. Die Arbeit wurde bisher 41-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Innovative Medicines Initiative, European Union's Seventh Framework Program, Agence Nationale de la Recherche under the "Investissement d'Avenir" program.
Abstract (Originalsprache)
Objective
The biologic diagnosis of primary Sjögren disease (SjD) mainly relies on anti‐Ro60/SSA antibodies, whereas the significance of anti‐Ro52/TRIM21 antibodies currently remains unclear. The aim of this study was to characterize the clinical, serological, biologic, transcriptomic, and interferon profiles of patients with SjD according to their anti‐Ro52/TRIM21 antibody status.
Methods
Patients with SjD from the European PRECISESADS (n = 376) and the Brittany Diagnostic Suspicion of primitive Sjögren's Syndrome (DIApSS); (n = 146) cohorts were divided into four groups: double negative (Ro52 − /Ro60 − ), isolated anti‐Ro52/TRIM21 positive (Ro52 + ), isolated anti‐Ro60/SSA positive (Ro60 + ), and double‐positive (Ro52 + /Ro60 + ) patients. Clinical information; EULAR Sjögren Syndrome Disease Activity Index, a score representing systemic activity; and biologic markers associated with disease severity were evaluated. Transcriptome data obtained from whole blood by RNA sequencing and type I and II interferon signatures were analyzed for PRECISESADS patients.
Results
In the DIApSS cohort, Ro52 + /Ro60 + patients showed significantly more parotidomegaly (33.3% vs 0%–11%) along with higher β2‐microglobulin ( P = 0.0002), total immunoglobulin ( P < 0.0001), and erythrocyte sedimentation rate levels ( P = 0.002) as well as rheumatoid factor (RF) positivity (66.2% vs 20.8%–25%) compared to other groups. The PRECISESADS cohort corroborated these observations, with increased arthritis ( P = 0.046), inflammation ( P = 0.005), hypergammaglobulinemia ( P < 0.0001), positive RF ( P < 0.0001), leukopenia ( P = 0.004), and lymphopenia ( P = 0.009) in Ro52 + /Ro60 + patients. Cumulative EULAR Sjögren Syndrome Disease Activity Index results further confirmed these disparities ( P = 0.002). Transcriptome analysis linked anti‐Ro52/TRIM21 antibody positivity to interferon pathway activation as an underlying cause for these clinical correlations.
Conclusion
These results suggest that the combination of anti‐Ro52/TRIM21 and anti‐Ro60/SSA antibodies is associated with a clinical, biologic, and transcriptional profile linked to greater disease severity in SjD through the potentiation of the interferon pathway activation by anti‐Ro52/TRIM21 antibodies. image
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- LBAI, UMR1227, INSERM, University of Western Brittany, Brest, France, and Centre Hospitalier Universitaire de Brest, Brest, France.
- Centre Hospitalier Universitaire de Brest, Brest, France.
- Center for Genomics and Oncological Research, Granada, Spain.
- LBAI, UMR1227, INSERM, University of Western Brittany, Brest, France.
ORCID-Profile: Eléonore Bettacchioli, Alain Saraux, Divi Cornec, Sophie Hillion, Jacques-Olivier Pers, Valérie Devauchelle-Pensec
Förderung
- Innovative Medicines Initiative
- European Union's Seventh Framework Program
- Agence Nationale de la Recherche under the "Investissement d'Avenir" program
- Seventh Framework Programme
Zitieren
APA
Bettacchioli, E., Saraux, A., Tison, A., Cornec, D., Dueymes, M., Foulquier, N., Hillion, S., Roguedas-Contios, A. M., Benyoussef, A. A., Alarcon-Riquelme, M. E., Pers, J. O., Devauchelle-Pensec, V., & PRECISESADS Clinical Consortium, and PRECISESADS Sjögren Consortium (2024). Association of Combined Anti‐Ro52 / TRIM21 and Anti‐Ro60 / SSA Antibodies With Increased Sjögren Disease Severity Through Interferon Pathway Activation. Arthritis & Rheumatology, 76(5), 751-762. https://doi.org/10.1002/art.42789
Vancouver
Bettacchioli E, Saraux A, Tison A, Cornec D, Dueymes M, Foulquier N, et al. Association of Combined Anti‐Ro52 / TRIM21 and Anti‐Ro60 / SSA Antibodies With Increased Sjögren Disease Severity Through Interferon Pathway Activation. Arthritis & Rheumatology. 2024;76(5):751-762. doi:10.1002/art.42789
BibTeX
@article{Bettacchioli2024,
author = {Bettacchioli, Eléonore and Saraux, Alain and Tison, Alice and Cornec, Divi and Dueymes, Maryvonne and Foulquier, Nathan and Hillion, Sophie and Roguedas-Contios, Anne-Marie and Benyoussef, Anas-Alexis and Alarcon-Riquelme, Marta E and Pers, Jacques-Olivier and Devauchelle-Pensec, Valérie and PRECISESADS Clinical Consortium, and PRECISESADS Sjögren Consortium, PRECISESADS Clinical Consortium, and PRECISESADS Sjögren Consortium},
title = {Association of Combined Anti‐Ro52 / TRIM21 and Anti‐Ro60 / SSA Antibodies With Increased Sjögren Disease Severity Through Interferon Pathway Activation},
journal = {Arthritis & Rheumatology},
year = {2024},
volume = {76},
number = {5},
pages = {751--762},
doi = {10.1002/art.42789}
}
EUVIMED